FIELD: biotechnology.
SUBSTANCE: disclosed is a method of treating cancer in a subject in need of such treatment, comprising administering to the subject a therapeutically effective amount of a population of propagated natural killer cells exhibiting increased resistance to transforming growth factor beta, compared to NK cells of natural origin, where the population of NK cells is activated and propagated in vitro in the presence of TGF-β and feeding leukaemia cells. Also disclosed are methods for producing a population of in vitro propagated natural killer cells for use in treating cancer, wherein the population of NK cells is activated and propagated in vitro in the presence of transforming growth factor beta and leukaemia feeder cells, wherein the population of expanded NK cells exhibits high resistance to TGF-β.
EFFECT: invention can be used in treating cancer in patients.
22 cl, 12 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR ASSESSING THE SENSITIVITY OF A TUMOR TO IMMUNO-ONCOLOGICAL DRUGS | 2021 |
|
RU2771760C1 |
| USE OF PARTICLES BASED ON CYTOPLASMIC MEMBRANE, LIPOSOMES AND EXOSOMES FOR ANALYZING ACTIVITY OF IMMUNE CELLS | 2020 |
|
RU2829443C2 |
| USE OF STIMULANT FOR ANALYZING ACTIVITY OF IMMUNE CELLS | 2020 |
|
RU2822517C2 |
| CHIMERIC ANTIGEN RECEPTORS WITH MUTATED CD28 COSTIMULATION DOMAINS | 2018 |
|
RU2800922C2 |
| METHOD FOR PRODUCTION OF NATURAL KILLER CELLS, AND COMPOSITION FOR CANCER TREATMENT | 2019 |
|
RU2780848C2 |
| DETERMINATION OF DOSE FOR IMMUNOTHERAPEUTIC AGENTS | 2017 |
|
RU2771717C2 |
| UNIVERSAL ANTIGEN PRESENTING CELLS AND THEIR USE | 2019 |
|
RU2809113C2 |
| METHOD AND COMPOSITIONS FOR CELLULAR IMMUNOTHERAPY | 2012 |
|
RU2688185C2 |
| METHOD FOR PREDICTION OF LIFE EXPECTANCY IN PATIENTS WITH METASTATIC TUMORS | 2023 |
|
RU2821659C1 |
| METHODS OF PREPARING ANTI-HUMAN PAPILLOMAVIRUS ANTIGEN T CELLS | 2014 |
|
RU2713333C2 |
